Migami has secured the licensing rights to proprietary QuSome technology and is in the process of acquiring the technology on a worldwide basis for all OTC and pharmaceutical applications. The QuSome technology can be delivered orally, topically and transmucosally.

QuSomes are spherical vesicles with a membrane composed of a Dag-Peg lipid used to deliver drugs or genetic material into a cell and can be composed of naturally derived Dap-Peg lipids with mixed lipid chains (e.g.. the cell membrane), thus delivering the QuSome contents with maximum efficiency and potency. Medical science has long recognized the considerable potential of QuSome molecules as a superior vehicle to deliver encapsulated drugs.

The growth rate for transdermal drug-delivery systems is expected to increase over 10% annually; worldwide market revenues are at USD 3 Billion - 56% within the United States, 32% within Europe and 7% within Japan. QuSome technology succeeds Liposome technology, a multi-billion dollar business, as the next evolutionary step in cosmetics, topical creams, and medicine.